SCLX
Scilex Holding Company Common Stock
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Scilex (SCLX) Stock: Buy, Sell, or Hold?
$1.62
+0.01 (+0.62%)
▲
5d:
-11.48%
30d:
-43.75%
90d:
-75.96%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 13, 2026
TODAY
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (91%)
Quality Score
52/100
Position
OVERSOLD
30-Day Fair Range
$1.79 – $3.07
Position: OVERSOLD
Forward P/E & Valuation
2.2x
CHEAP
vs 6.7x historical avg
Wall Street Target
$490.00
+30146.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$1.61 / $2.17
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: SCLX is down 11.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When SCLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$6.85
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$4.26
61.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SCLX is currently trading at $1.62, which is considered oversold relative to its 30-day fair value range of $1.79 to $3.07. From a valuation perspective, the stock is trading at a discount (Forward PE: 2.2) compared to its historical average (6.7). Remarkably, the market is currently pricing in an annual earnings decline of 30.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SCLX is in a strong downtrend. The price is currently testing key support at $1.61. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SCLX scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $490.00 (+30146.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SCLX is in a strong downtrend. The price is currently testing key support at $1.61. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SCLX scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $490.00 (+30146.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.79 -
$3.07
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
Trading Range & Key Levels
30-Day Trading Range
$1.79 -
$3.07
Current vs Trading Range
OVERSOLD
Support Level
$1.61
Resistance Level
$2.17
Current Trend
Strong Downtrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 30146.9% below Wall St target ($490.00)
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
2.22
Wall Street Target
$490.00
(+30146.9%)
Revenue Growth (YoY)
-22.8%
Valuation Discount vs History
-30.9% cheaper
PE vs Historical
2.2 vs 6.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-30.9%
(market-implied from PE analysis)
1-Year Target
$1.46
(-10%)
2-Year Target
$1.31
(-19%)
3-Year Target
$1.18
(-27%)
3-Yr Target (if PE normalizes)
(PE: 2→7)
$3.57
(+120%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.2 to 6.7
Stabilization Target:
$4.89
(+201.9%)
PE Expansion Potential:
+201.9%
Share SCLX Analysis
Share this live SCLX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (SCLX)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
StockTwits user with 497 followers expressed a bullish opinion regarding the potential performance of $DVLT, $SRNE, and $SCLX.
Key Retail Themes:
potential performance of $DVLT, $SRNE, and $SCLX
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 4:21 AM ET
Data refreshes hourly during market hours. Next update: 5:21 AM
Data refreshes hourly during market hours. Next update: 5:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SCLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABBV
AbbVie Inc |
STRONG BUY
29 analysts |
$306 | 48 HOLD |
|
BIIB
Biogen Inc |
BUY
36 analysts |
$266 | 43 HOLD |
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1453 | 27 SELL |
|
MRK
Merck & Company Inc |
BUY
28 analysts |
$162 | 50 HOLD |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$175 | 37 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive SCLX Research Pages
